Clinical Data Wave crashes on obesity drug update; Kodiak’s reboot pays dividends BioPharma DiveWave s drug, which is meant to improve body composition, disappointed investors but was defended by analysts.Clinical DataMetabolic & GLP-1Read full story pharminent March 26, 2026 (Last updated: March 27, 2026) BioPharma Dive Wave s drug, which is meant to improve body composition, disappointed investors but was defended by analysts. Clinical DataMetabolic & GLP-1Read full story Post navigation Previous: Maze tumbles despite positive data for kidney disease drugNext: FDA clears Denali drug in ‘clear step’ for rare disease biotechs Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026